

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
11 November 2021 (11.11.2021)



(10) International Publication Number
WO 2021/225833 A1

(51) International Patent Classification:

C07C 311/11 (2006.01) C07C 67/08 (2006.01)
C07D 513/08 (2006.01) C07D 213/71 (2006.01)
C07D 513/10 (2006.01) C07D 303/04 (2006.01)
C07C 29/36 (2006.01)

(21) International Application Number:

PCT/US2021/029523

(22) International Filing Date:

28 April 2021 (28.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/020,951 06 May 2020 (06.05.2020) US

(71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: LANGILLE, Neil, Fred; c/o Amgen Inc., Law Department – Patent Operations, One Amgen Center Drive - M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). TEDROW, Jason, S.; c/o Amgen Inc., Law Department – Patent Operations, One Amgen Center Drive - M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). TRUONG, Jonathan, Vinh-Phu; c/o Amgen Inc., Law Department – Patent Operations, One Amgen Center Drive - M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). MILBURN, Robert, Ronald; c/o Amgen Inc., Law Department – Patent Operations, One Amgen Center Drive - M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). ARENA, Alessandro; c/o Amgen Inc., Law Department – Patent Operations, One Amgen Center Drive - M/S 28-5-A, Thousand Oaks, California 91320-1799 (US).

(74) Agent: FRIEDRICHSEN, Bernard, P.; Amgen Inc., Law Department - Patent Operations M/S 28-5-A, One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: SYNTHESIS OF SULFONAMIDE INTERMEDIATES



(57) Abstract: Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound Z that can be used to prepare them. In particular, provided herein are processes for synthesizing compound A1, and salts or solvates thereof and compound A2, and salts and solvates thereof. [INSERT COMPOUNDS HERE]

WO 2021/225833 A1